[1] |
World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
|
[2] |
World Health Organization . Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization, 2010.
|
[3] |
马丙乾, 孙敬涛, 刘慧君 , 等. 河南省濮阳市1119株结核分枝杆菌耐药情况分析. 中国防痨杂志, 2014,36(4):279-285.
doi: 10.3969/j.issn.1000-6621.2014.04.011
URL
|
[4] |
World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
|
[5] |
World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis,2016 update. Geneva: World Health Organization, 2016.
URL
pmid: 27748093
|
[6] |
刘会, 董雅坤, 张娜 , 等. 耐多药肺结核患者不同化疗方案疗效及不良反应的临床观察. 河北医科大学学报, 2015,36(3):265-268.
doi: 10.3969/j.issn.1007-3205.2015.03.006
URL
|
[7] |
李琦, 姜晓颖, 梁建琴 , 等. 含左氧氟沙星或含莫西沙星方案治疗耐多药肺结核的疗效分析. 中国防痨杂志, 2016,38(6):436-442.
doi: 10.3969、j.issn.1000-6621.2016.06.004
|
[8] |
刘智, 傅佳鹏, 杨梁梓 , 等. 左氧氟沙星和莫西沙星治疗耐多药肺结核临床疗效比较. 临床肺科杂志, 2017,22(4):711-714.
doi: 10.3969/j.issn.1009-6663.2017.04.038
URL
|
[9] |
施亚平 . 左氧氟沙星联合抗结核化疗方案治疗40例复治涂阳肺结核患者临床疗效观察. 现代诊断与治疗, 2014,25(7):1608-1609.
|
[10] |
翁丽珠 . 利福布丁联合克拉霉素治疗复治涂阳结核病的疗效观察. 海峡药学, 2012,24(12):147-148.
doi: 10.3969/j.issn.1006-3765.2012.12.075
URL
|
[11] |
张红伟, 高志东, 贺晓新 , 等. 个体化方案治疗耐多药肺结核患者不良反应分析. 中国防痨杂志, 2016,38(2):133-138.
doi: 10.3969/j.issn.1000-6621.2016.02.012
URL
|
[12] |
孔雯, 刘巧, 陆伟 , 等. 标准化耐多药肺结核化疗方案的不良反应及治疗转归情况分析. 中华疾病控制杂志, 2014,18(7):610-612.
|
[13] |
徐彩红, 李仁忠, 阮云洲 , 等. 耐多药肺结核治疗不良反应发生情况分析. 中华疾病控制杂志, 2013,17(3):243-245.
|
[14] |
Yang TW, Park HO, Jang HN , et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore), 2017,96(28):e7482.
doi: 10.1097/MD.0000000000007482
URL
|
[15] |
弭凤玲, 王黎霞, 李亮 , 等. 中国全球基金耐多药结核病项目阶段性实施结果分析. 中国防痨杂志, 2010,32(11):700-704.
|
[16] |
梁永志 . 大环内酯类抗生素心脏毒性防治. 中国实用医药, 2008,3(5):49-50.
doi: 10.3969/j.issn.1673-7555.2008.05.029
URL
|
[17] |
Schembri S, Williamson PA, Short PM , et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, 2013,346:f1235.
doi: 10.1136/bmj.f1235
URL
|
[18] |
刘芳, 陈文超, 孔旭黎 . 氟喹诺酮类抗生素心脏毒性机制的研究进展. 现代生物医学进展, 2008,8(12):2596-2597, 2588.
|
[19] |
Haverkamp W, Kruesmann F, Fritsch A , et al. Update on the cardiac safety of moxifloxacin. Curr Drug Saf, 2012,7(2):149-163.
doi: 10.2174/157488612802715735
URL
|
[20] |
李艳红, 吴江贵, 周桂芝 , 等. 耐多药结核病患者治疗依从性的影响因素分析. 中国感染控制杂志, 2015,14(9):593-596.
doi: 10.3969/j.issn.1671-9638.2015.09.004
URL
|
[21] |
Tupasi TE, Garfin AM, Kurbatova EV , et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis, 2016,22(3):491-502.
doi: 10.3201/eid2203.151788
URL
|